DPP-4 Antagonists: Benefits, Risks, and the Future
Dipeptidyl peptidase-4 inhibitors, of the incretin class of antidiabets drugs, are weight neutral, avoid hypoglycemia, and result in an average reduction in HbA1c of 0.5% to 1.0%. Here, an expert on the DPP-4s and their evolution discusses pros and cons. (Source: Consultant Live)
Source: Consultant Live - February 25, 2013 Category: Primary Care Source Type: news